Business
Avicanna to Supply Australian Market with Cannabis-Based Medicinal Products Through Distribution Agreement with Cannvalate
Avicanna to Supply Australian Market with Cannabis-Based Medicinal Products Through Distri...
About this update from Avicanna Inc
[{"type":"text","content":"\n\n\n\nAvicanna to Supply Australian Market with Cannabis-Based Medicinal Products Through Distribution Agreement with Cannvalate\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Feb. 24, 2020\n\n\n\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/\n TORONTO, Feb. 24, 2020 /CNW/ - Avicanna Inc. (\"Avicanna\" or the \"Company\") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an importation and distribution agreement (the \"Agreement\") with Cannvalate Pty Ltd. (\"Cannvalate\"), to supply its Rho Phyto™ advanced medical cannabis products (the \"Rho Products\") to provide to patients under the Australian Therapeutic Goods Administration Special Access Scheme, as well cannabis active pharmaceutical ingredients (the \"APIs\"). Avicanna has also agreed to supply Cannvalate with a line of advanced cannabinoid phyto-therapeutic products that Avicanna has chosen to offer on a white-labelled basis (the \"White-Label Products\", collectively with the Rho Products and APIs, the \"Products\").\n\n \n \n\n \n\"After significant due diligence into the Australian market and its operators we are pleased to be able to introduce Cannvalate as our partners in the region. Our two companies are aligned on a strictly medical approach backed by sustainable processes, data driven R&D and clinical development which will be to the benefit of the Australian patients and medical community at large.\"  stated Aras Azadian, Chief Executive Officer of Avicanna. \n\"We are delighted to assist Avicanna with market entry to Australia which is one of the fastest growing pureplay medicinal cannabis markets globally. We have been particularly impressed by their attention to quality processes...